Lisata Therapeutics

LSTA

Current ValuationThe current P/E ratio is -0.65, within the reasonable range, cheaper than 21.09% of the time in the past 5 years, and the industry ranks 168/606, the industry Median -1.87.

-0.653xP/E
Stock price$1.06Earnings per share$-1.62

Historical Valuation

P/E ratioTypical rangeMedian

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.
021426384

The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x30x60x90x120x150x
P/E ratio
Name/Symbol
GILDUSGilead Sciences
-60.73x150.60%$196.77B
MRNAUSModerna
-25.19x17.00%$79.39B
CSLLYUSCSL Limited
-25.37x--$65.44B
NTRAUSNatera
-303.43x5.57%$58.36B
RVMDUSRevolution Medicines
-22.29x61.94%$39.42B
ROIVUSRoivant Sciences
-97.80x146.69%$26.04B
BNTXUSBioNTech SE
-11.16x18.90%$21.82B
INSMUSInsmed
-23.28x75.01%$20.38B
BBIOUSBridgebio Pharma
-19.26x27.56%$13.32B
SMMTUSSummit Therapeutics
-13.51x19.85%$11.57B
MDGLUSMadrigal Pharma
-31.11x51.30%$10.11B
PCVXUSVaxcyte
-8.87x47.91%$9.44B
TWSTUSTwist Bioscience
-69.94x28.63%$9.56B
KYMRUSKymera Therapeutics
-31.87x5.24%$9.55B
IBRXUSImmunityBio
-8.34x151.32%$8.28B
CYTKUSCytokinetics
-9.44x6.85%$8.44B
ARWRUSArrowHead Pharma
-26.04x35,923.70%$8.33B
SYREUSSpyre Therapeutics
-54.54x45.60%$8.19B
ABVXUSAbivax SA
-16.21x22.99%$7.54B
IONSUSIonis Pharma
-12.77x49.51%$7.22B

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.